LONDON, Aug 13 (Reuters) - The European Medicines Agency said on Wednesday
it was assessing two cases of a potentially deadly brain disease reported last
month in multiple sclerosis (MS) patients being treated with the drug Tysabri.
The London-based agency said it would then decide whether any changes were
necessary to the currently approved label for product, which is made by Elan
Corp Plc and Biogen Idec Inc .
Shares in both companies slumped following the July 31 news of the latest
cases of the brain infection known as progressive multifocal leukoencephalopathy
(PML).
Tysabri was withdrawn from the market in 2005 after three patients developed
PML. It returned in 2006 but the latest cases may prompt physicians to reduce
the number of patients they start on the drug, analysts fear.
More than 31,800 patients were being treated with Tysabri as of the end of
June and second-quarter sales totaled $200 million.
(Reporting by Ben Hirschler; Editing by Paul Bolding) Keywords: ELAN
BIOGEN/TYSABRI
tf.TFN-Europe_newsdesk@thomsonreuters.com
jlw
COPYRIGHT
Copyright Thomson Financial News Limited 2008. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|